| # | Country | Total Patents | |
|---|---|---|---|
| #1 | WIPO (World Intellectual Property Organization) | 5 | |
| #2 | Canada | 3 | |
| #3 | China | 3 | |
| #4 | EPO (European Patent Office) | 3 | |
| #5 | Mexico | 3 | |
| #6 | United States | 2 | |
| #7 | South Africa | 1 |
| # | Industry | |
|---|---|---|
| #1 | Pharmaceuticals | |
| #2 | Biotechnology | |
| #3 | Machines | |
| #4 | Organic fine chemistry |
| # | Technology | |
|---|---|---|
| #1 | Therapeutic chemical compounds | |
| #2 | Microorganisms | |
| #3 | Unspecified technologies | |
| #4 | Heterocyclic compounds |
| # | Name | Total Patents |
|---|---|---|
| #1 | Saarma Mart | 17 |
| #2 | Karelson Mati | 16 |
| #3 | Pilv Mehis | 7 |
| #4 | Truve Erkki | 5 |
| #5 | Sarmiento Cecilia | 5 |
| #6 | Merits Andres | 5 |
| #7 | Olspert Allan | 5 |
| #8 | Mart Saarma | 3 |
| #9 | Mati Karelson | 3 |
| #10 | Bespalov Maxim | 1 |
| Publication | Filing date | Title |
|---|---|---|
| WO2011070177A2 | Methods of facilitating neural cell survival using gdnf family ligand (gfl) mimetics or ret signaling pathway activators | |
| WO2009144365A1 | Use of oligonucleotides with modified bases as antiviral agents | |
| EP2212420A2 | Use of oligonucleotides with modified bases as antiviral agents | |
| US2011152346A1 | Use of Oligonucleotides with Modified Bases in Hybridization of Nucleic Acids | |
| CA2651031A1 | Antisense agents combining strongly bound base - modified oligonucleotide and artificial nuclease |